cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5066/p99gwppg
title: Evaporation data from Lake Mead, Nevada and Arizona

description: This U.S. Geological Survey data release presents monthly evaporation estimates from Lake Mead, Nevada and Arizona. Data are updated approximately annually. The spreadsheet includes five worksheets: (1) Read_Me worksheet contains information relevant to understanding the data contained in the rest of the worksheets. (2) Monthly_EC_Met worksheet includes data measured at a land-based station (USGS site identification number 360500114465601) using primarily eddy covariance measurement methods: uncorrected evaporation, latent- and sensible-heat fluxes, net radiation, air temperature, wind speed, and relative humidity. Values are monthly averages computed by averaging daily values except as noted. Monthly values are marked as estimated when a significant portion of daily values are estimated. (3) Monthly_Energy-Budget_Data worksheet includes computed data used to correct measured evaporation for energy balance. Computed data include monthly values for change in stored heat, net advection, turbulent flux, available energy, energy balance ratio, energy balance closure, and Bowen ratio. Change in stored heat was calculated based on methods in Earp and Moreo (2021). Net advection was calculated based on data estimated by the Bureau of Reclamation 24-Month Study (2022). Values are monthly averages or computed from monthly averages. (4) Annual_Energy_Balance worksheet includes annual averages of the Monthly_Energy_Balance data and the annual average values for energy-balance corrected sensible and latent heat fluxes. Values are annual averages or computed from annual averages. (5) Monthly_Evaporation_Estimates worksheet includes measured evaporation, corrected (most probable) evaporation, and energy balance ratio (EBR) adjusted evaporation, in feet. Values are monthly averages or computed from monthly averages. Data were processed according to methods described in Moreo and Swancar (2013) and Earp and Moreo (2021). References Cited: Bureau of Reclamation, Lower Colorado Region website: Operation Plan for Colorado River System Reservoirs (24-Month Study), accessed September 1, 2022 at https://www.usbr.gov/lc/region/g4000/24mo/index.html. Earp, K.J., and Moreo, M.T., 2021, Evaporation from Lake Mead and Lake Mohave, Nevada and Arizona, 2010?2019: U.S. Geological Survey Open-File Report 2021?1022, 36 p., https://doi.org/10.3133/ofr20211022. Moreo, M.T., and Swancar, A., 2013, Evaporation from Lake Mead, Nevada and Arizona, March 2010 through February 2012: U.S. Geological Survey Scientific Investigations Report 2013?5229, 40 p., http://dx.doi.org/10.3133/sir20135229.
DOI: 10.34740/kaggle/dsv/4816753
title: Egypt Gold Prices | Daily Updated
DOI: 10.5281/zenodo.7510529
title: Water Supply Tipping Point Data and Code

description: This publication provides code, WaterSupplyTippingPoints.R, to calculate tipping points in water supply by using a time series of deficit data. The code uses data files that are produced from an agent-based model that simulates water supply dynamics. The code uses deficit data to calculate a water supply performance metric, Sustainability Index, and implements a decision tree change point detection method detects change points. The code implements a tipping point rule that is applied to select a change point as a tipping point. Data files of deficits that are used as input are described and published at https://zenodo.org/record/3971213. The code can be executed for four management scenarios and 16 shifting climate scenarios. Management Strategy 1 is no management. Management Strategy 2 is retrofitting. Management Strategy 3 is retrofitting with reactive drought restrictions. Management Strategy 4 is retrofitting with proactive drought restrictions. The 16 shifting climate scenarios correspond to shifting factors equal to 0.25 - 1.0, increasing in 0.05 increments. For each of the 64 modeling scenarios (16 climate settings X 4 management strategies), 100 simulations were run to capture stochasticity. The output from the code are provided in a set of .csv files, attached here. Data files (TippingPoints-mgmt1.csv, TippingPoints-mgmt2.csv, TippingPoints-mgmt3.csv, TippingPoints-mgmt4.csv) list the 100 tipping points that were identified for each shifting factor and each management strategy. Columns (V1, V2, ... V100) are 100 unique and randomized simulations for each modeling scenario. Rows correspond to shifting factors, where Row 1 is shifting factor 0.25, and Row 16 is shifting factor 1.00.
DOI: 10.5281/zenodo.7510528
title: Water Supply Tipping Point Data and Code

description: This publication provides code, WaterSupplyTippingPoints.R, to calculate tipping points in water supply by using a time series of deficit data. The code uses data files that are produced from an agent-based model that simulates water supply dynamics. The code uses deficit data to calculate a water supply performance metric, Sustainability Index, and implements a decision tree change point detection method detects change points. The code implements a tipping point rule that is applied to select a change point as a tipping point. Data files of deficits that are used as input are described and published at https://zenodo.org/record/3971213. The code can be executed for four management scenarios and 16 shifting climate scenarios. Management Strategy 1 is no management. Management Strategy 2 is retrofitting. Management Strategy 3 is retrofitting with reactive drought restrictions. Management Strategy 4 is retrofitting with proactive drought restrictions. The 16 shifting climate scenarios correspond to shifting factors equal to 0.25 - 1.0, increasing in 0.05 increments. For each of the 64 modeling scenarios (16 climate settings X 4 management strategies), 100 simulations were run to capture stochasticity. The output from the code are provided in a set of .csv files, attached here. Data files (TippingPoints-mgmt1.csv, TippingPoints-mgmt2.csv, TippingPoints-mgmt3.csv, TippingPoints-mgmt4.csv) list the 100 tipping points that were identified for each shifting factor and each management strategy. Columns (V1, V2, ... V100) are 100 unique and randomized simulations for each modeling scenario. Rows correspond to shifting factors, where Row 1 is shifting factor 0.25, and Row 16 is shifting factor 1.00.
DOI: 10.6084/m9.figshare.21728042
title: Hematopoietic stem cell transplantation activity in Mexico during the COVID19 pandemic: on the way to recovery

description: To analyze the number of HSCTs performed in 2019 vs. 2020 and report the status of transplant centers (TCs) during and a year after the COVID-19 pandemic. We performed a comprehensive cross-sectional nationwide study including active TCs interrogating HSCT activity from 2019 through September 2021. An electronic survey was sent to TCs and consisted of items regarding the number and characteristics of procedures performed and were compared yearly. Changes to their institutions’ transplant policies and practices during the COVID19 pandemic were also documented. Fifty centers were invited to participate, 33 responded. Most TCs were part of the public health system (63.7%). Almost half are in the country’s capital, Mexico City (45.5%). Most centers performed &lt;10 procedures per year. The number of HSCTs decreased from 835 in 2019–505 in 2020 (<i>p</i> &lt; .001), representing a 40% reduction in transplant activity. The monthly transplant rate in 2021 increased to 58.3, compared to 42 in 2020 and close to 69.5 in 2019 (<i>p</i> &lt; .001). All types of HSCTs decreased excluding haploidentical transplants. All institutions treated patients with COVID19, and over two-thirds experienced some form of hospital reconversion. Transplant activity stopped completely in 23 TCs (70%) during the pandemic with a median closure duration of 9.9 months (range, 1-21). In 2021, 9.1% of TCs remained closed, all of them in the public setting. The limited transplant activity in Mexico decreased significantly during the pandemic but is recovering and nearly in pre-pandemic levels.
DOI: 10.6084/m9.figshare.21728042.v1
title: Hematopoietic stem cell transplantation activity in Mexico during the COVID19 pandemic: on the way to recovery

description: To analyze the number of HSCTs performed in 2019 vs. 2020 and report the status of transplant centers (TCs) during and a year after the COVID-19 pandemic. We performed a comprehensive cross-sectional nationwide study including active TCs interrogating HSCT activity from 2019 through September 2021. An electronic survey was sent to TCs and consisted of items regarding the number and characteristics of procedures performed and were compared yearly. Changes to their institutions’ transplant policies and practices during the COVID19 pandemic were also documented. Fifty centers were invited to participate, 33 responded. Most TCs were part of the public health system (63.7%). Almost half are in the country’s capital, Mexico City (45.5%). Most centers performed &lt;10 procedures per year. The number of HSCTs decreased from 835 in 2019–505 in 2020 (<i>p</i> &lt; .001), representing a 40% reduction in transplant activity. The monthly transplant rate in 2021 increased to 58.3, compared to 42 in 2020 and close to 69.5 in 2019 (<i>p</i> &lt; .001). All types of HSCTs decreased excluding haploidentical transplants. All institutions treated patients with COVID19, and over two-thirds experienced some form of hospital reconversion. Transplant activity stopped completely in 23 TCs (70%) during the pandemic with a median closure duration of 9.9 months (range, 1-21). In 2021, 9.1% of TCs remained closed, all of them in the public setting. The limited transplant activity in Mexico decreased significantly during the pandemic but is recovering and nearly in pre-pandemic levels.
DOI: 10.6084/m9.figshare.20180259
title: Genetic mutations associated with blood count abnormalities in myeloid neoplasms

description: Myelodysplastic syndromes (MDS) predominantly present with varying degrees of cytopenia, while myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) exhibit proliferative features. Genetic defects underlying different complete blood count (CBC) alterations remain to be defined. We aimed to evaluate mutations and impacts on abnormal blood counts in MDS and MDS/MPN. MDS and MDS/MPN patients were recruited and sequenced by targeted next-generation sequencing. Clinical parameters, especially CBC, were evaluated for the association with genetic abnormalities and clinical outcomes. A total of 168 patients with myeloid neoplasms were recruited (92 cases of low-risk MDS, 57 cases of high-risk MDS and 19 cases of MDS/MPN). Compared to low-risk MDS and MDS/MPN, patients with high-risk MDS were presented with more severe neutropenia with 17.5% showing absolute neutrophil counts (ANC) lower than 0.5 × 10<sup>9</sup>/L. Patients with MDS/MPN more commonly harboured mutations and had a higher number of mutations per case than low-risk MDS (94.7% vs. 56.5%; <i>p</i> &lt; 0.001 and 3 vs. 1; <i>p</i> &lt; 0.001, respectively). Patients with <i>SF3B1</i> mutations showed lower haemoglobin levels than wild-type (7.9 vs. 8.4 g/dL, <i>p</i> = 0.02), but were associated with normal platelet counts (286 vs. 93 × 10<sup>9</sup>/L; <i>p</i> &lt; 0.001). Patients with <i>U2AF1</i> mutations were associated with more severe leukopenia than wild-type (3 vs. 4.18 × 10<sup>9</sup>/L; <i>p</i> = 0.02). <i>KRAS</i> mutations were associated with monocytosis (<i>p</i> &lt; 0.001). Multivariate analysis revealed high-risk MDS, MDS/MPN, severe neutropenia (ANC &lt; 0.5 × 10<sup>9</sup>/L), and mutations in <i>ASXL1</i> and <i>SETBP1</i> were associated with inferior survival outcomes. Certain mutations were related to more severe anaemia, lower white blood cell count or monocytosis in Asian MDS and MDS/MPN patients.
DOI: 10.6084/m9.figshare.20180259.v1
title: Genetic mutations associated with blood count abnormalities in myeloid neoplasms

description: Myelodysplastic syndromes (MDS) predominantly present with varying degrees of cytopenia, while myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) exhibit proliferative features. Genetic defects underlying different complete blood count (CBC) alterations remain to be defined. We aimed to evaluate mutations and impacts on abnormal blood counts in MDS and MDS/MPN. MDS and MDS/MPN patients were recruited and sequenced by targeted next-generation sequencing. Clinical parameters, especially CBC, were evaluated for the association with genetic abnormalities and clinical outcomes. A total of 168 patients with myeloid neoplasms were recruited (92 cases of low-risk MDS, 57 cases of high-risk MDS and 19 cases of MDS/MPN). Compared to low-risk MDS and MDS/MPN, patients with high-risk MDS were presented with more severe neutropenia with 17.5% showing absolute neutrophil counts (ANC) lower than 0.5 × 10<sup>9</sup>/L. Patients with MDS/MPN more commonly harboured mutations and had a higher number of mutations per case than low-risk MDS (94.7% vs. 56.5%; <i>p</i> &lt; 0.001 and 3 vs. 1; <i>p</i> &lt; 0.001, respectively). Patients with <i>SF3B1</i> mutations showed lower haemoglobin levels than wild-type (7.9 vs. 8.4 g/dL, <i>p</i> = 0.02), but were associated with normal platelet counts (286 vs. 93 × 10<sup>9</sup>/L; <i>p</i> &lt; 0.001). Patients with <i>U2AF1</i> mutations were associated with more severe leukopenia than wild-type (3 vs. 4.18 × 10<sup>9</sup>/L; <i>p</i> = 0.02). <i>KRAS</i> mutations were associated with monocytosis (<i>p</i> &lt; 0.001). Multivariate analysis revealed high-risk MDS, MDS/MPN, severe neutropenia (ANC &lt; 0.5 × 10<sup>9</sup>/L), and mutations in <i>ASXL1</i> and <i>SETBP1</i> were associated with inferior survival outcomes. Certain mutations were related to more severe anaemia, lower white blood cell count or monocytosis in Asian MDS and MDS/MPN patients.
DOI: 10.6084/m9.figshare.21215527
title: The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

description: To assess the clinical and healthcare resource burden among C5 inhibitor (C5i)-treated patients with paroxysmal nocturnal haemoglobinuria (PNH), using patient-reported data. This web-based, cross-sectional survey (01FEB2021–31MAR2021) of adults with PNH treated with eculizumab (France, Germany, UK) or ravulizumab (Germany) included: patient characteristics; treatment patterns/dosage; haematological outcomes (haemoglobin [Hb] levels, transfusions, thrombotic events, breakthrough haemolysis); and medical encounters. Treatment and Hb-level subgroup differences were assessed with statistical significance tests. Among 71 patients, 98.6% were C5i-treated for ≥3 months. The majority (with reported Hb levels) had levels ≤12.0 g/dL (85.7%; <i>n</i> = 54/63). The mean Hb level was 10.2 g/dL (standard deviation [SD]: 2.0; median 10.0 g/dL). Treatment with above label-recommended doses was reported by 30.4% (eculizumab) and 5.3% (ravulizumab) of patients. Within the past 12 months among patients treated with C5i for ≥1 year: 24.1% had ≥1 transfusion; 3.2% had ≥1 thrombosis; and 28.6% had ≥1 breakthrough haemolysis. Among all patients, 26.8% and 31.0% reported emergency department/room [ER] and inpatient visits, respectively. Mean annual, per-patient all-cause medical encounters were: 0.5 (ER); 1.9 (inpatient); and overall outpatient visits ranged by setting from 2.0 to 6.4. Most encounters were PNH-related, with means of 0.4 (ER); 1.8 (inpatient); and 1.6–5.4 (outpatient). Primary haematological and medical encounter outcomes were similar between treatment as well as Hb-level subgroups, with almost no statistically significant differences. Despite at least 3 months of C5i treatment, high proportions of patients with PNH reported low haemoglobin levels and required transfusions and hospitalizations, which suggests remaining unmet needs.
DOI: 10.6084/m9.figshare.21215527.v1
title: The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

description: To assess the clinical and healthcare resource burden among C5 inhibitor (C5i)-treated patients with paroxysmal nocturnal haemoglobinuria (PNH), using patient-reported data. This web-based, cross-sectional survey (01FEB2021–31MAR2021) of adults with PNH treated with eculizumab (France, Germany, UK) or ravulizumab (Germany) included: patient characteristics; treatment patterns/dosage; haematological outcomes (haemoglobin [Hb] levels, transfusions, thrombotic events, breakthrough haemolysis); and medical encounters. Treatment and Hb-level subgroup differences were assessed with statistical significance tests. Among 71 patients, 98.6% were C5i-treated for ≥3 months. The majority (with reported Hb levels) had levels ≤12.0 g/dL (85.7%; <i>n</i> = 54/63). The mean Hb level was 10.2 g/dL (standard deviation [SD]: 2.0; median 10.0 g/dL). Treatment with above label-recommended doses was reported by 30.4% (eculizumab) and 5.3% (ravulizumab) of patients. Within the past 12 months among patients treated with C5i for ≥1 year: 24.1% had ≥1 transfusion; 3.2% had ≥1 thrombosis; and 28.6% had ≥1 breakthrough haemolysis. Among all patients, 26.8% and 31.0% reported emergency department/room [ER] and inpatient visits, respectively. Mean annual, per-patient all-cause medical encounters were: 0.5 (ER); 1.9 (inpatient); and overall outpatient visits ranged by setting from 2.0 to 6.4. Most encounters were PNH-related, with means of 0.4 (ER); 1.8 (inpatient); and 1.6–5.4 (outpatient). Primary haematological and medical encounter outcomes were similar between treatment as well as Hb-level subgroups, with almost no statistically significant differences. Despite at least 3 months of C5i treatment, high proportions of patients with PNH reported low haemoglobin levels and required transfusions and hospitalizations, which suggests remaining unmet needs.
DOI: 10.6084/m9.figshare.18998664
title: Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan

description: Current guidelines for essential thrombocythemia (ET) patients recommend different treatment approaches based on thrombosis risk stratification models. However, these recommendations may not be applicable to some patients under real clinical settings. Therefore, we carried out a retrospective real-world validation study. Thrombosis-free survival (TFS) was compared between treatment naïve ET patients receiving different treatment approaches. ET patients were stratified by three representative risk models, the conventional, the International Prognostic Score for thrombosis in ET (IPSET-thrombosis), and revised IPSET-thrombosis. Treatment decisions were largely made by individual physicians, taking into account patient preferences and backgrounds. A total of 179 ET patients were included, and thrombotic events were observed in 26 patients. TFS was significantly longer in high-risk patients of all risk models receiving a combination of cytoreductive therapy (CRT) and antiplatelet therapy (APT) compared to CRT alone. Similar results were seen in intermediate-risk patients stratified by IPSET-thrombosis. In contrast, in very low- and low-risk patients of all risk models, TFS was not affected by addition of CRT, indicating that observation or APT alone is an appropriate treatment approach for these patients. We demonstrate that current guidelines provide optimal treatment approaches for Japanese ET patients under real-world clinical settings.
DOI: 10.6084/m9.figshare.18998664.v1
title: Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan

description: Current guidelines for essential thrombocythemia (ET) patients recommend different treatment approaches based on thrombosis risk stratification models. However, these recommendations may not be applicable to some patients under real clinical settings. Therefore, we carried out a retrospective real-world validation study. Thrombosis-free survival (TFS) was compared between treatment naïve ET patients receiving different treatment approaches. ET patients were stratified by three representative risk models, the conventional, the International Prognostic Score for thrombosis in ET (IPSET-thrombosis), and revised IPSET-thrombosis. Treatment decisions were largely made by individual physicians, taking into account patient preferences and backgrounds. A total of 179 ET patients were included, and thrombotic events were observed in 26 patients. TFS was significantly longer in high-risk patients of all risk models receiving a combination of cytoreductive therapy (CRT) and antiplatelet therapy (APT) compared to CRT alone. Similar results were seen in intermediate-risk patients stratified by IPSET-thrombosis. In contrast, in very low- and low-risk patients of all risk models, TFS was not affected by addition of CRT, indicating that observation or APT alone is an appropriate treatment approach for these patients. We demonstrate that current guidelines provide optimal treatment approaches for Japanese ET patients under real-world clinical settings.
DOI: 10.6084/m9.figshare.19166357
title: Highly specific functional equivalence of XN-HPC for optimum CD34+ cell count in harvested allogeneic bone marrow stem cell products

description: To establish a reliable XN-HPC cutoff, for an effective CD34 + cell count of ≥2 × 10<sup>6</sup>cells/kg of the recipient’s body weight, in harvested bone marrow products in allogenic transplantation. The study was carried out in two phases. In retrospective Phase 1, data from 47 donors were analyzed. Sysmex analyzer XN-20 and BD FACS Calibur were employed to process XN-HPC and CD34 + cell enumeration, respectively. To make the two variables comparable, both XN-HPC and CD34 + cell counts were reported as the number of cells/kg of the recipient’s body weight. Spearman’s rank correlation coefficient was calculated for CD34 + cells and XN-HPC, followed by the calculation of the receiver operating characteristic (ROC) curve to identify the XN-HPC value which could effectively predict the cutoff of ≥2 × 10<sup>6</sup> CD34 + cells/kg of the recipient’s body weight. In Phase 2, the computed XN-HPC cutoff was validated in a prospective set of 53 donors by obtaining the positive and negative predictive values. Statistically significant correlation was obtained between XN-HPC and CD34 + cell count with Spearman’s rho of 0.54 (<i>p</i>-value &lt;0.001). The optimal XN-HPC cutoff, for the required CD34 + ve cell count of ≥2 × 10<sup>6</sup> cells/kg of the recipient’s body weight, was calculated to be ≥2.80×10<sup>6</sup> cells/kg of the recipient’s body weight with the specificity and sensitivity of 100% and 31%, respectively. The ROC curve demonstrated the area under the curve to be 0.74. Phase 2 validation revealed 100% PPV. For harvested bone marrow products with XN-HPC of ≥2.80×10<sup>6</sup> cell/kg of the recipient’s body weight, CD34 + cell enumeration by flow cytometry can safely be disposed of.